首页> 外文OA文献 >Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

【2h】

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

机译：Galiximab的II期试验（抗CD80单克隆抗体）加里妥昔单抗（CALGB 50402）：滤泡淋巴瘤国际预后指数（FLIPI）评分是预测前期免疫治疗响应性的预测性

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
M.S. Czuczman; J.P. Leonard; S. Jung; J.L. Johnson; E.D. Hsi; J.C. Byrd; B.D. Cheson;
展开▼
作者单位

展开▼
年度 2012
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
中文文献

1. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness (vol 23, pg 2356, 2012) [J] . Czuczman M. S., Leonard J. P., Jung S., Annals of oncology: official journal of the European Society for Medical Oncology . 2018,第11期

机译：Galiximab的II期试验（抗CD80单克隆抗体）加里妥昔单抗（CalgB 50402）：卵泡淋巴瘤国际预后指数（FLIPI）评分是预测前期免疫治疗响应性（第23卷，PG 2356,2012）
2. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular lymphoma international prognostic index (FLIPI) score is predictive of upfront immunotherapy responsiveness [J] . CzuczmanM.S., LeonardJ.P., JungS., Annals of oncology: official journal of the European Society for Medical Oncology . 2012,第9期

机译：加利昔单抗（抗CD80单克隆抗体）加利妥昔单抗（CALGB 50402）的II期试验：滤泡性淋巴瘤国际预后指数（FLIPI）得分可预测前期免疫疗法的反应性
3. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness [J] . M. S. Czuczman1* J. P. Leonard2 S. Jung3 J. L. Johnson3 E. D. Hsi4 J. C. Byrd5 and B. D. Cheson6 Annals of Oncology . 2012,第9期

机译：加利昔单抗（抗CD80单克隆抗体）加利妥昔单抗（CALGB 50402）的II期试验：滤泡性淋巴瘤国际预后指数（FLIPI）评分可预测前期免疫疗法的反应性
4. Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness [O] . M S Czuczman, J P Leonard, S Jung, -1

机译：加利昔单抗（抗CD80单克隆抗体）加利妥昔单抗（CALGB 50402）的II期临床试验：滤泡性淋巴瘤国际预后指数（FLIPI）评分可预测前期免疫疗法的反应性
5. Corrections to “Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness” [O] . M.S. Czuczman, J.P. Leonard, S. Jung, 2018

机译：矫正“Galiximab的第二阶段试验”（抗CD80单克隆抗体）加里妥昔单抗（CalgB 50402）：卵泡淋巴瘤国际预后指数（FLIPI）评分是预测前期免疫治疗响应性“

Phase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness

著录项

引文网络

相似文献

相关主题

期刊订阅